Suppression of blastogenesis and proliferation of CD4+ T cells by highly polyreactive anti-Face-2 mAbs (e.g., TFL-006 and TFL-007) point out that they can be potential immunotherapeutic agents for controlling tumor progression. This evidence concerns the gene CD4 and neoplasm.